Form 8-K - Current report:
SEC Accession No. 0001640455-21-000038
Filing Date
2021-02-12
Accepted
2021-02-12 08:14:07
Documents
14
Period of Report
2021-02-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20210210.htm   iXBRL 8-K 38089
  Complete submission text file 0001640455-21-000038.txt   184239

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20210210.xsd EX-101.SCH 2424
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20210210_cal.xml EX-101.CAL 714
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20210210_def.xml EX-101.DEF 1651
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20210210_lab.xml EX-101.LAB 24975
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20210210_pre.xml EX-101.PRE 13191
7 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20210210_htm.xml XML 11205
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

EIN.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 21622935
SIC: 2836 Biological Products, (No Diagnostic Substances)